Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
September 2021—Verichem Laboratories offers a selection of ready-to-use carbon dioxide reference materials. The five-level standard kit along with an optional level F are intended for calibration and/or calibration verification of clinical systems and are suited for use with ion-selective electrode and wet testing methodologies.
September 2021—Tribvn Healthcare, based in Paris, announced a partnership with Cypath, a Lyon, France–based private diagnostics group comprising more than 60 pathologists, in which Tribvn will digitalize Cypath’s workflow. The group’s laboratory aims to scan two million slides per year.
September 2021—Qiagen’s NeuMoDx HAdV Quant Assay for the identification and quantification of human adenovirus DNA has received CE-IVD certification for the European Union and other countries that accept this mark. The tests can be run in true random access along with laboratory-developed tests.
September 2021—Quidel received the CE mark for its Savanna multiplex molecular analyzer and Savanna Respiratory Viral Panel-4 assay. Savanna is a multiplex molecular platform that enables analysis of up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes.
September 2021—The FDA issued an emergency use authorization to Ortho Clinical Diagnostics for its Vitros Immunodiagnostic Products Anti-SARS-CoV-2 IgG Quantitative test.
September 2021—Biocept received a positive final local coverage determination that expands Medicare coverage for use of its Target Selector assay to identify the HER2 biomarker from circulating tumor cells. The coverage determination from the Centers for Medicare and Medicaid Services molecular diagnostics program was effective July 4.
September 2021—Bio-Rad launched its Reliance SARS-CoV-2/FluA/FluB RT-PCR Kit (IVD) for European markets after having met the CE-IVD mark requirements.
September 2021—Immunovia has received approval to begin patient testing for the IMMray PanCan-d blood test for the early detection of pancreatic cancer. Approval was received Aug. 3 from the Massachusetts Department of Public Health, and the company received its CLIA Certificate of Registration on June 21.
September 2021—The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
September 2021—Inova Diagnostics announced FDA 510(k) clearance of its Aptiva system and Aptiva Celiac Disease IgA assay. Aptiva is a fully automated digital multianalyte system for the clinical laboratory. Aptiva received the CE mark in August 2020.
